Dr. Peter Ansell discusses the use of novel RNA-based gene expression profiling technologies for clinical and preclinical oncology research.

The ability to predict the cancer treatment for each individual patient is one of the most pivotal goals of oncology precision medicine. To accomplish this, scientists must gain an improved understanding of the biology driving each patient’s tumor. Differential gene expression can identify which molecular pathways are aberrantly regulated and thereby inform which treatment will be most effective.

Often such studies are limited due to sample size or quality issues, long turnaround times for lab processing, difficulty in deciphering the data, and insufficient reproducibility for an eventual companion diagnostic test.

In this talk, Dr. Peter Ansell from Abbvie discusses how he and his team overcame some of these challenges using novel technologies available on the market. He presents a case study to demonstrate the utility of such technologies and their benefits over traditional gene expression profiling methods. Lastly, he discusses the future of biomarker-based treatments for oncology patients and the impact HTG is making in the field.

Key Topics Include:

  • Overview of advances in RNA-based gene expression profiling
  • Introduction to ultra-efficient gene expression profiling (GEP) technology and its importance in maximizing reliable information while conserving precious samples
  • Evaluation of the utility of ultra-efficient GEP in real-world applications, such as for clinical and preclinical oncology research
  • Discussion about the benefits of novel profiling technologies compared to traditional methods

Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video viewer.



Scientific Director and Research Fellow
Precision Medicine, Oncology

Dr. Ansell’s PhD research at University of Missouri focused on the regulation of gene expression by estrogen receptors. He determined estrogen receptors could regulate the activity of Nrf2, a transcription factor that regulates expression of genes involved in protecting cells from oxidative stress (Mol Cell Endocrinol 2005, Endocrinology 2004). As a postdoctoral researcher at Harvard Medical School, he moved on to investigate gene expression, cellular differentiation and proliferation of pituitary tumors. With more than 15 years of industry experience he is leading a team which designs and implements impactful precision medicine strategies across much of AbbVie’s solid tumor pipeline.

Senior Vice President
Research & Development

Dr. Navratil is the SVP of R&D at HTG Molecular Diagnostics, responsible for the oversight and execution of the company’s research and development plans, as well HTG’s commercial laboratory operations. Prior to joining HTG, Dr. Navratil served in a variety of product development leadership roles, most recently with Beckman Coulter Diagnostics and Danaher, where he led the development of in vitro diagnostic tests for a variety of disease states. Dr. Navratil earned his MS. degree in Biochemistry and Biotechnology, and PhD. in Biotechnology from the Slovak University of Technology, and completed his postdoctoral training at the Linkoping University in Sweden and at the University of Minnesota. Dr. Navratil is a member of the editorial board of Biotechnology Letters.

Production Partner

HTG Molecular Diagnostics, Inc.

HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.

Additional Content From Scientist.com

Related Content